# Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus

> **NCT00220129** · PHASE2 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 16 (actual)

## Conditions studied

- Oesophageal Carcinoma

## Interventions

- **DRUG:** Epirubicin, Cisplatin, Capecitabine
- **PROCEDURE:** Surgical Resection

## Key facts

- **NCT ID:** NCT00220129
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2009-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220129, "Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00220129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*